Skip to main content

Table 4 Cost-effectiveness results in three patient subgroups

From: The cost-effectiveness of B-type natriuretic peptide-guided care in compared to standard clinical assessment in outpatients with heart failure in Tehran, Iran

Subgroup

BNP

Standard clinical assessment

Incremental cost per QALY gained (BNP vs. standard clinical Assessment)

Cost (USD)

QALYs

Cost (USD)

QALYs

45–55 years

$1100

2.07

$1280

1.24

Dominant

55–65 years

$1540

1.65

$1400

1.35

USD 466

65–75 years

$2700

1.24

$2050

1.02

USD 2954

  1. BNP, B-type natriuretic peptide; QALYs, quality-adjusted life-years; USD, United States Dollars